home / stock / aqst / aqst quote
Last: | $2.48 |
---|---|
Change Percent: | 0.0% |
Open: | $2.41 |
Close: | $2.48 |
High: | $2.48 |
Low: | $2.36 |
Volume: | 1,143,974 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.48 | $2.41 | $2.48 | $2.48 | $2.36 | 1,143,974 | 07-05-2024 |
$2.41 | $2.41 | $2.41 | $2.44 | $2.36 | 677,157 | 07-04-2024 |
$2.41 | $2.41 | $2.41 | $2.44 | $2.36 | 677,157 | 07-03-2024 |
$2.42 | $2.38 | $2.42 | $2.44 | $2.36 | 688,802 | 07-02-2024 |
$2.45 | $2.63 | $2.45 | $2.63 | $2.34 | 1,652,672 | 07-01-2024 |
$2.6 | $2.6 | $2.6 | $2.69 | $2.565 | 12,672,298 | 06-28-2024 |
$2.59 | $2.42 | $2.59 | $2.6 | $2.42 | 1,701,035 | 06-27-2024 |
$2.42 | $2.31 | $2.42 | $2.44 | $2.24 | 1,828,656 | 06-26-2024 |
$2.31 | $2.47 | $2.31 | $2.475 | $2.305 | 1,560,588 | 06-25-2024 |
$2.43 | $2.56 | $2.43 | $2.58 | $2.41 | 1,423,272 | 06-24-2024 |
$2.56 | $2.52 | $2.56 | $2.59 | $2.465 | 3,116,333 | 06-21-2024 |
$2.5 | $2.64 | $2.5 | $2.65 | $2.45 | 2,213,997 | 06-20-2024 |
$2.68 | $2.76 | $2.68 | $2.78 | $2.643 | 788,295 | 06-19-2024 |
$2.68 | $2.76 | $2.68 | $2.78 | $2.643 | 788,295 | 06-18-2024 |
$2.73 | $2.7 | $2.73 | $2.755 | $2.59 | 1,736,088 | 06-17-2024 |
$2.69 | $2.75 | $2.69 | $2.75 | $2.67 | 698,206 | 06-14-2024 |
$2.77 | $2.83 | $2.77 | $2.86 | $2.745 | 619,246 | 06-13-2024 |
$2.81 | $2.81 | $2.81 | $2.93 | $2.795 | 721,261 | 06-12-2024 |
$2.81 | $2.72 | $2.81 | $2.855 | $2.715 | 877,754 | 06-11-2024 |
$2.76 | $2.7 | $2.76 | $2.78 | $2.57 | 1,849,489 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
Aquestive Therapeutics Inc. Company Name:
AQST Stock Symbol:
NASDAQ Market:
Aquestive Therapeutics Inc. Website:
WARREN, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...
Anaphylm pharmacokinetic results unaffected by oral cavity exposure to liquids of different temperatures and pH Remains on track to complete Anaphylm supportive clinical studies and expects to request pre-NDA meeting with FDA in the third quarter 2024 Continues to anticipate filin...
WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...